Background: Active efflux is a common mechanism of resistance to fluoroquinolones in Streptococcus pneumoniae. Two efflux systems have been described so far in this species: PmrA, a member of the major facilitator superfamily; and the two ABC transporters PatA and PatB. We studied the inducibility of expression of pmrA, patA and patB by using subinhibitory concentrations of fluoroquinolones.
Introduction
Streptococcus pneumoniae is a leading cause of respiratory tract infections, including community-acquired pneumonia (CAP). 1, 2 The so-called respiratory fluoroquinolones (levofloxacin, moxifloxacin and gemifloxacin) 3 are active in the treatment of CAP. 1, 2 However, the use of levofloxacin has been associated with a decrease in bacterial susceptibility and subsequent clinical failures. 4 High-level fluoroquinolone resistance is mainly due to mutations in structural genes for the GyrA subunit of DNA gyrase and for the ParC subunit of topoisomerase IV. 5 However, there is increasing evidence that active efflux can play an important role in decreasing the susceptibility of the isolates, 6 -8 with ciprofloxacin and norfloxacin often being used as reporter antibiotics in this context.
PmrA, a member of the major facilitator superfamily (MFS), was the first efflux pump shown to confer resistance to norfloxacin and ciprofloxacin. 9 More recently, an efflux system belonging to the ATP binding cassette (ABC) superfamily and composed of two transporters encoded by patA (SP2075) and patB (SP2073) was identified. 10, 11 Expression of these genes was increased in strains with decreased susceptibility to fluoroquinolones, 7, 12, 13 and induced by ciprofloxacin or norfloxacin. 10, 14 These studies, carried out with a reference strain and derivative mutants, were limited to fluoroquinolones that are substrates for this efflux system. In the present study, we have compared induction of expression of pmrA, patA and patB by five fluoroquinolones (putative good or poor substrates) in various strains including clinical isolates. Because fluoroquinolones and the DNA-damaging agent mitomycin C can induce a competence pathway and chromosomal transformation in S. pneumoniae, 15, 16 we examined whether mitomycin C was able to induce patA and patB expression as part of a global stress response. In a nutshell, we report that: (i) all fluoroquinolones can induce patA and patB expression in a concentration-dependent manner; (ii) the extent of overexpression depends on the strain rather than on the inducer; and (iii) mitomycin C is able to trigger overexpression of patA and patB, confirming that this efflux system is part of a general stress response related to DNA damage. 14 
Materials and methods

Bacterial strains and growth conditions
The five strains studied were: (i) the reference S. pneumoniae ATCC 49619; (ii) two laboratory mutants (SP334, derived from S. pneumoniae ATCC 49619, and SP335, derived from the clinical isolate SP32, selected after 13 days of exposure to ciprofloxacin 12 ); and (iii) two clinical isolates (SP295 and SP13) (see Table 1 ). Cultures were performed at 378C in a 5% CO 2 atmosphere using Todd-Hewitt broth supplemented with 1% yeast extract (THY; BD, Franklin Lakes, NJ, USA) or Mueller-Hinton agar supplemented with 5% defibrinated sheep blood (International Medical Products, Brussels, Belgium).
Determination of MICs
MICs of fluoroquinolones and of ethidium bromide and acriflavine (two well-known substrates for efflux pumps) were determined by the serial 2-fold macrodilution method in Mueller-Hinton agar supplemented with 5% defibrinated horse blood, with an inoculum of 10 5 bacteria per spot. 12, 17 The efflux inhibitor reserpine was used at a final concentration of 20 mg/L. 18 
DNA techniques
Chromosomal DNA was purified with the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Plasmid DNA was prepared using the Plasmid Midi Preps Kit (Qiagen) and transformed into Escherichia coli.
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Restriction enzymes and T4 DNA ligase were obtained from New England Biolabs (Ipswich, MA, USA). Blunt-ending of restricted plasmid DNA was performed by the addition of 1 U of Klenow enzyme (New England Biolabs) and 33 mM deoxynucleoside triphosphates to the reaction mixture at the end of enzymatic digestion. Restriction fragments were purified from agarose gels with the QIAquick Gel Extraction Kit (Qiagen). PCR amplifications were performed according to the manufacturer's protocol for BIOTAQ Red DNA polymerase (Gentaur, Kampenhout, Belgium). The sequences of the primers used are shown in Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
Quantitative real-time PCR
S. pneumoniae was grown overnight at 378C in a 5% CO 2 atmosphere on Mueller-Hinton agar supplemented with 5% defibrinated sheep blood. Bacteria were resuspended in 15 mL of THY medium supplemented or not with inducers at an optical density (620 nm) of 0.2-0.4. For induction, bacteria were grown for up to 6 h at 378C in 5% CO 2 . For experiments examining the reversal of induction, bacteria were harvested by centrifugation (3000 g for 10 min) after 4 h of culture in the presence of antibiotic at half the MIC, washed once at room temperature in drugfree medium and centrifuged, and the pellet was then resuspended in THY drug-free medium and cultured for up to 5 h. Bacteria were harvested by centrifugation (5000 g for 5 min at 48C) and the pellets were frozen and kept at 2808C for at least 30 min before nucleic acid extraction. Total RNA extraction and reverse transcription were performed as previously described. 12 Real-time PCR was performed in an iQ cycler (Bio-Rad Laboratories, Hercules, CA, USA) in 25 mL reaction mixtures containing 12.5 mL of iQ SYBR Green Supermix (2×), 400 nM of forward and reverse primers and 5 mL of cDNA in RNase/DNase-free water. The rpoD and proC genes were used as references to normalize transcript levels, as specified by PrimerDesign (Southampton, UK).
Inactivation of patA, patB and pmrA genes
To inactivate patA or patB, the strains were transformed with genomic DNA of M246 or M240 strains, which have a magellan2 minitransposon inserted in either patA or patB. 13 Transformants were selected on Mueller-Hinton agar containing 5% defibrinated sheep blood supplemented with 100 mg/L spectinomycin. Gene inactivation was verified by PCR. 13 To inactivate pmrA, a 1 kb BamHI-KpnI PCR fragment, amplified with the PmrARec-F and PmrARec-R primers (Table S1 ) and carrying the pmrA gene, was cloned in BamHI-KpnI-restricted pUC18. 20 The plasmid was then cleaved in the insert by ClaI and blunt-ended with Klenow enzyme. The aad9 gene of magellan2 conferring resistance to spectinomycin 21 was amplified by PCR with the Spec-1 and Spec-2 primers (Table S1 ), ligated with the linearized plasmid to generate pUC18VpmrA::spt and transformed into S. pneumoniae strain R6. Inactivation of pmrA was confirmed by PCR using the PmrA-Delta-F and PmrA-Delta-R primers.
Quinolone resistance-determining region (QRDR) sequencing
The QRDRs of gyrA, parC and parE were amplified and sequenced using the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and a Genetic Analyzer 3100 (Applied Biosystems) as previously described. 12 Antibiotics, other substrates and pump inhibitor Levofloxacin, moxifloxacin and gemifloxacin were obtained as microbiological standards from Aventis Pharma (Antony, France), Bayer HealthCare (Leverkusen, Germany) and LG Life Sciences (Seoul, Korea), respectively. Other antibiotics, substrates or inducers were obtained as pure substances from Sigma-Aldrich (St Louis, MO, USA).
Results
Antibiotic susceptibility of the strains Table 1 summarizes the MICs of the five fluoroquinolones and of acriflavine and ethidium bromide, determined in the absence or presence of reserpine. The MICs of norfloxacin, ciprofloxacin, acriflavine and ethidium bromide were significantly (≥2 dilutions; 1 dilution for acriflavin and SP334) higher for SP334, SP335, SP295 and SP13 than for S. pneumoniae ATCC 49619. The MICs of levofloxacin and gemifloxacin were significantly higher in SP334, SP335 and SP13 [reaching or exceeding the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical resistance breakpoint for levofloxacin]. Moxifloxacin MIC was increased by two dilutions only against SP335 (but remained below the EUCAST resistance breakpoint). El Garch et al.
In the presence of reserpine, the MICs of acriflavine and ethidium bromide were similar to those for the wild-type strain, suggesting an efflux mechanism in the four strains. For fluoroquinolones, restoration of wild-type MICs by reserpine was complete for SP334 and SP295, but only partial for SP335 and SP13, which have mutations in the QRDR (Table 1) .
Role of PmrA, PatA and PatB in antibiotic resistance
The expression of pmrA, patA and patB was quantified by realtime PCR in all strains ( Figure 1 ). As compared with S. pneumoniae ATCC 49619, the four resistant strains overexpressed patA and patB to levels ranging from 4.4-fold for patA in SP334 to 13.6-fold for patB in SP13. In contrast, only SP335 and SP13 showed modest overexpression of pmrA.
Every gene was inactivated in each of the five strains, and the MICs for the disruptants were determined (Table 1) . For all strains, inactivation of either patA or patB reduced the MIC of acriflavine and ethidium bromide to a value similar to that for S. pneumoniae ATCC 49619 in the presence of reserpine. Likewise, the MICs of fluoroquinolones for patA-or patB-inactivated strains were reduced (+1 dilution) to those measured for the corresponding parental strain in the presence of reserpine (or even lower for SP335). In contrast, inactivation of pmrA did not cause a marked decrease in MICs (0 to 1 dilution).
Induction of patA, patB or pmrA expression by fluoroquinolones
The expression of these genes was then measured in bacteria grown for 4 h in the presence of fluoroquinolones at half their MIC (preliminary experiments with ciprofloxacin showed that this concentration caused the maximal effect; see Figure S1 , available as Supplementary data at JAC Online http://jac. oxfordjournals.org). All fluoroquinolones were potent inducers of patA and patB in strains SP335 and SP295, but showed a lower effect in strains ATCC 49619 and SP334 and no effect for norfloxacin and levofloxacin in strain SP13 (Figure 2) . In contrast, the expression of pmrA remained unaffected or even decreased upon exposure to fluoroquinolones. Specificity of induction was tested with tetracycline and chloramphenicol under the same conditions, but no change in the expression of patA, patB or pmrA was observed (data not shown).
Kinetics of induction
To follow the kinetics of induction of patA and patB and the time needed to revert to basal level, strains ATCC 49619 and SP335 were used as they showed a low and high basal level of patA/ patB expression, respectively. Ciprofloxacin and moxifloxacin were selected as substrate and non-substrate (Figure 3) . In both strains, a lag phase of 30 -40 min was observed during which no change in expression level was observed, followed by increased expression levels over time. Reduction in expression was detected as soon as the drugs were removed and reversal to original pre-exposure levels was obtained after 3 -4 h. To test if changes in patA and patB expression over time did not result from growth variations, expression of the genes under non-inducing conditions in bacteria from the exponential to the stationary phase was measured and no differences were seen. Conversely, there was no change in optical density over the 6 h of induction, indicating absence of significant growth over the time frame of the experiment (see Figure S2 , available as Supplementary data at JAC Online http://jac.oxfordjournals.org/).
Induction of patA/patB and of the competence regulon by mitomycin C DNA-damaging agents or antibiotics are capable of inducing the SOS response, 22 or a competence pathway in bacteria devoid of an SOS system, such as S. pneumoniae. 15, 16, 23 We therefore examined whether mitomycin C, a DNA-damaging agent known to induce competence in S. pneumoniae, 15, 16 was also able to induce expression of patA and patB. In parallel, we quantified the expression levels of two genes involved in competence via the com regulon, 16 namely recA 24 and ssbB. 25, 26 The expression of these genes upon induction by ciprofloxacin or mitomycin C was largely parallel to that of patA and patB, with a correlation coefficient of 0.879 and 0.897 for ssbB and recA versus patA and patB, respectively (see Figure S3 , available as Supplementary data at JAC Online http://jac.oxfordjournals.org/).
Discussion
Two important observations were made. Our study shows that PatA and PatB play a major role in fluoroquinolone resistance in the two clinical isolates and the two in vitro mutants examined here, while PmrA does not, confirming the data of Piddock et al. 27 and Garvey and Piddock. 13 Inactivation of either patA or patB restored full susceptibility to ethidium bromide or acriflavine in the four strains, or to fluoroquinolones in those strains that did not harbour mutations in the genes encoding the target proteins. El Garch et al.
In contrast, pmrA inactivation had only a marginal effect, in agreement with other studies. 7, 11, 28 First, resistance mediated by PatA/PatB did not affect all fluoroquinolones to the same extent, with norfloxacin being the most affected, followed by ciprofloxacin, gemifloxacin, levofloxacin and finally moxifloxacin. This is in agreement with a previous ranking established for fluoroquinolone susceptibility to efflux in S. pneumoniae 6, 29, 30 or in S. aureus, 31 suggesting that hydrophilic molecules are better substrates. We extend here this observation to other fluoroquinolones, but show that moxifloxacin, the most lipophilic molecule among those tested here, was little affected by the overexpression of PatA/PatB. Interestingly this ranking seems to apply to efflux pumps of the ABC superfamily (like PatA/PatB) as well as to those of the MFS superfamily (such as NorA in S. aureus). This observation may suggest that common molecular or physicochemical determinants in substrates are recognized by non-phylogenetically related transporters.
Second, inactivation of either patA or patB is sufficient to restore full susceptibility to fluoroquinolones and no phenotypic discrepancies are observed between patA and patB knockouts with respect to fluoroquinolone, acriflavine or ethidium susceptibility. Together with the facts that (i) homologues of PatA and PatB appear as pairs of proteins working together 13 and (ii) predictions of topologies for PatA and PatB propose four to seven transmembrane segments for each of these proteins [using either TMPRED (http://www.ch.embnet.org/software/ TMPRED_form.html) or SOSUI (http://bp.nuap.nagoya-u.ac.jp/ sosui)], these observations suggest that the two proteins may constitute a heterodimeric ABC-type multidrug transporter 13, 32 or, at least, a need to interact to confer fluoroquinolone resistance. 10 When bacteria are exposed to antibiotics, dyes, solvents or detergents, they can adapt by inducing the expression of efflux systems. 33, 34 It has been shown that patA and patB expression of a wild-type S. pneumoniae and of an in vitro resistant mutant thereof is inducible upon exposure to norfloxacin or ciprofloxacin. 10, 14 This observation is extended here by showing that induction is obtained (i) for all fluoroquinolones tested, whether substrates of PatA/PatB or not, and (ii) not only in a wildtype strain, but also in in vitro mutants and in clinical isolates overexpressing patA and patB under non-inducing conditions. Increase in expression develops rapidly, irrespective of the fluoroquinolone used, and is fully reversible. Because induction seems specific to fluoroquinolones, is observed even in strains with preexisting high basal efflux expression and is observed with inducers that are or are not substrates, it is tempting to speculate that overexpression is the consequence of a change in global regulatory responses induced by fluoroquinolones.
Regulation of ABC-type efflux transporters involves local regulators, repressors or activators, as well as global transcriptional regulators. 32 -34 Yet the regulators of patA and patB expression are unknown. A microarray analysis showed that exposure of S. pneumoniae to ciprofloxacin induces the expression of genes involved in the competence pathway, mismatch repair system or replication. 14 We found here a coexpression of patA and patB and of two genes of the competence pathway 15, 16, 23 upon exposure to ciprofloxacin or the DNA-damaging agent mitomycin C. This strongly suggests that the overexpression of patA and patB observed upon induction by fluoroquinolones is not only dependent upon local regulators, but is also part of a global response related to the stress imposed by their interaction with DNA. 22, 35 The data presented here may have important implications for the clinical use of fluoroquinolones. Induction of patA and patB expression by subinhibitory concentrations of any fluoroquinolone may contribute to increased levels of resistance to the molecules of the class that are substrates for efflux. As MICs may remain below or at the limit of the susceptibility breakpoint for the more potent fluoroquinolones, this highlights the usefulness of antibiotics like norfloxacin or ciprofloxacin in laboratory screens and/or for identifying resistance mechanisms at the molecular level. This inducible character also compromises the potential importance of efflux inhibitors that would act as competitive substrates, as illustrated by the cross-resistance to reserpine observed in a strain overexpressing patA. The column headings in Table 1 of this article were misaligned in the published version. The corrected version of Table 1 is reproduced on the next page. The publisher apologizes for this error. 
